Edgewise Therapeutics, Inc. (EWTX) — SEC Filings
Edgewise Therapeutics, Inc. (EWTX) — 50 SEC filings. Latest: 10-Q (May 7, 2026). Includes 17 8-K, 10 SC 13G/A, 7 10-Q.
View Edgewise Therapeutics, Inc. on SEC EDGAR
Overview
Edgewise Therapeutics, Inc. (EWTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 20, 2025: Edgewise Therapeutics, Inc. filed an 8-K on November 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 44 neutral, 1 mixed. The dominant filing sentiment for Edgewise Therapeutics, Inc. is neutral.
Filing Type Overview
Edgewise Therapeutics, Inc. (EWTX) has filed 2 4, 7 10-Q, 17 8-K, 1 DEFA14A, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 5 SC 13G, 4 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of EWTX's 31 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$40.666M |
| EPS | -$0.39 |
| Debt-to-Equity | 0.04 |
| Cash Position | $563.3M |
| Operating Margin | N/A |
| Total Assets | $583.466M |
| Total Debt | $24.819M |
Key Executives
- David M. E. Brown
- Sarah K. Gordon
- Sarah Boyce
- David Epstein
- Barbara Fiorini
- B. Shayne Kennedy
- Dr. Sarah Boyce
- Mr. David Epstein
- Abigail P. Johnson
Industry Context
Edgewise Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by significant R&D investment, long development cycles, and high failure rates. Success hinges on scientific innovation, clinical trial efficacy, and navigating complex regulatory pathways.
Top Tags
filing (5) · sec-filing (5) · financials (5) · institutional-ownership (5) · amendment (5) · financial-condition (4) · 8-k (4) · annual-meeting (4) · 10-Q (4) · results-of-operations (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $40.666M | Increased from $34.129M in Q3 2024 |
| Net Loss (YTD Sep 2025) | $117.579M | Increased from $94.151M in YTD Sep 2024 |
| Research and Development Expenses (YTD Sep 2025) | $107.795M | Increased from $90.596M in YTD Sep 2024 |
| Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025) | $563.3M | Increased from $459.216M at Dec 31, 2024 |
| Net Proceeds from January 2024 Offering | $231.9M | Significantly boosted capital resources |
| Accumulated Deficit (Sep 30, 2025) | $496.2M | Indicates historical losses |
| Shares Outstanding (Oct 31, 2025) | 105,868,434 | Reflects recent equity issuances |
| Increase in R&D Expenses (YTD) | 19% | Reflects increased clinical trial activity |
| Net Loss | $94.84M | for the three months ended June 30, 2025, indicating increased R&D spend |
| Revenue | 0 | for both Q2 2025 and YTD 2025, consistent with a pre-commercial biotech |
| Total Assets | $95.1B | Financial position as of March 31, 2025 |
| Total Liabilities | $0.33M | Financial position as of March 31, 2025 |
| Total Equity | $95.2M | Financial position as of March 31, 2025 |
| Cash and Cash Equivalents | $94.8M | Liquidity as of March 31, 2025 |
| Annual Meeting Date | 20250613 | Shareholders will vote on proposals at this date. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant stake in Edgewise Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The continued institutional ownership by FMR LLC will provide a level of stability to Edgewise Therapeutics' stock price.","entity":"Edgewise Therapeutics, Inc.","targetDate":"2024-12-31","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Edgewise Therapeutics, Inc. (EWTX)?
Edgewise Therapeutics, Inc. has 50 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 10 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EWTX filings?
Across 50 filings, the sentiment breakdown is: 3 bullish, 2 bearish, 44 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Edgewise Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Edgewise Therapeutics, Inc. (EWTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Edgewise Therapeutics, Inc.?
Key financial highlights from Edgewise Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EWTX?
The investment thesis for EWTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Edgewise Therapeutics, Inc.?
Key executives identified across Edgewise Therapeutics, Inc.'s filings include David M. E. Brown, Sarah K. Gordon, Sarah Boyce, David Epstein, Barbara Fiorini and 4 others.
What are the main risk factors for Edgewise Therapeutics, Inc. stock?
Of EWTX's 31 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Edgewise Therapeutics, Inc.?
Recent forward-looking statements from Edgewise Therapeutics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant stake in Edgewise Therapeutics for the foreseeable future.","entity":"FMR and 1 other predictions.